Anteris Technologies Global Corp

anteristech.com

What Do They Do?

Develops a transcatheter aortic valve system and sells regenerative tissue products to medical-device companies and distributors.

How Do They Make Money?

Customers buy ADAPT tissue products directly; sales are counted when delivered to their premises, and contracts typically have no significant unusual payment terms beyond 30 days.

FY2025 revenue

Who Are Their Customers?

It has sold regenerative tissue products mainly to 4C, a medical-technology company, and LeMaitre, a medical-products distributor; sales are direct.

Do Revenues Turn Into Profits?

No. It lost $94.1M in FY2025.

Operating income, FY2025

−4908% of revenue

▲ +20% (Loss) vs FY2024 (−$78.4M, −2899%)

Net income, FY2025

−4921% of revenue

▲ +23% (Loss) vs FY2024 (−$76.3M, −2822%)

Free cash flow, FY2025

−4169% of revenue

▲ +26% (Loss) vs FY2024 (−$63.5M, −2350%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +63%; vs $618K in Q2 FY2025
Net income: ▲ +40% (Loss); vs −$20.8M in Q2 FY2025

Apr 29, 2026 Ends development funding for v2v heart-valve repair program Anteris will pay a $400,000 break fee and make no further development contributions; v2v's initial shareholders may buy out its stake or reduce it.

Who Do They Compete With?

Competes with Edwards Lifesciences and Medtronic

Comments